Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
Authors:
- Sandra SalillasSSSandra Salillas
- Jelmer RaaijmakersJRJelmer Raaijmakers
- Rob E. AarnoutseRARob E. Aarnoutse
- Elin M. SvenssonESElin M. Svensson
- Erik van Den HomberghEHErik van Den Hombergh
- Ralf StemkensRSRalf Stemkens
- Heiman F. L. WertheimHWHeiman F. L. Wertheim
- Wouter HoefslootWHWouter Hoefsloot
- Jakko van IngenJIJakko van Ingen
Open Access
- 6 March 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0115723
Abstract
Mycobacterium avium complex pulmonary disease is treated with an azithromycin, ethambutol, and rifampicin regimen, with limited efficacy. The role of rifampicin is controversial due to inactivity, adverse effects, and drug interactions. Here, we evaluated the efficacy of clofazimine as a substitute for rifampicin in an intracellular hollow-fiber infection model. THP-1 cells, which are monocytes isolated from peripheral blood from an acute monocytic leukemia patient, were infected with M. avium ATCC 700898 and exposed to a regimen of azithromycin and ethambutol with either rifampicin or clofazimine. Intrapulmonary pharmacokinetic profiles of azithromycin, ethambutol, and rifampicin were simulated. For clofazimine, a steady-state average concentration was targeted. Drug concentrations and bacterial densities were monitored over 21 days. Exposures to azithromycin and ethambutol were 20%–40% lower than targeted but within clinically observed ranges. Clofazimine exposures were 1.7 times higher than targeted. Until day 7, both regimens were able to maintain stasis. Thereafter, regrowth was observed for the rifampicin-containing regimen, while the clofazimine-containing regimen yielded a 2 Log 10 colony forming unit (CFU) per mL decrease in bacterial load. The clofazimine regimen also successfully suppressed the emergence of macrolide tolerance. In summary, substitution of rifampicin with clofazimine in the hollow-fiber model improved the antimycobacterial activity of the regimen. Clofazimine-containing regimens merit investigation in clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic GranulomasAntimicrobial Agents and Chemotherapy, 2014
- Comparative Study of the Effects of Antituberculosis Drugs and Antiretroviral Drugs on Cytochrome P450 3A4 and P-GlycoproteinAntimicrobial Agents and Chemotherapy, 2014
- Efficacy of Clarithromycin and Ethambutol for Mycobacterium avium Complex Pulmonary Disease. A Preliminary StudyAnnals of the American Thoracic Society, 2014
- Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infectionsInternational Journal of Antimicrobial Agents, 2013
- The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Tissue Distribution and Deposition of Clofazimine in Mice Following Oral Administration with or without IsoniazidArzneimittelforschung, 2007
- Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Effect of Sex and AIDS Status on the Plasma and Intrapulmonary Pharmacokinetics of RifampicinClinical Pharmacokinetics, 2004
- Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremicAIDS, 1997
- Double-Blind Controlled Clinical Trial of Clofazimine in Reactive Phases of Leprotamous LeprosyBMJ, 1970